An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma - SAFETY EXTENSION
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Foresee Pharmaceuticals
- 30 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
- 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Mar 2016 New trial record